Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Go back

UK-RES-2101574 August 2021


Prescribing Trimbow

Each dose contains three compounds for the treatment of asthma1

Each metered dose contains:

  • 100mcg beclometasone
  • 6mcg formoterol
  • 10 mcg glycopyrronium


Each delivered dose contains:

  • 87mcg beclometasone
  • 5mcg formoterol
  • 9mcg glycopyrronium

Trimbow contains beclometasone, formoterol and glycopyrronium in a solution formulation resulting in an aerosol with extrafine particles.1

* Delivered dose is the dose leaving the mouthpiece, Metered dose is the dose leaving the valve.

Trimbow is taken twice daily[[1,2]]

Trimbow pMDI 87/5/9 is a 3 in 1 inhaler (ICS/LABA/LAMA) indicated for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1

Trimbow is licensed for use with an AeroChamber Plus® Spacer [[1,3]]

As a pMDI, Trimbow has the option to be used with an AeroChamber Plus® spacer.

  • Patients already familiar with a pMDI + spacer can use the same inhalation technique with Trimbow 1,4
  • The option of using Trimbow pMDI with an AeroChamber Plus® spacer can reduce oropharyngeal deposition and assist with hand-breath coordination 1,5

Trimbow device with an AeroChamber Plus attached

Dose counter[[1]]

Inclusion of a dose counter means patients can keep track of their remaining Trimbow doses at any time.


AeroChamber Plus® is a registered trademark of Trudell Medical International.

ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressurised metered dose inhaler.

For additional information to share with your patients who have been prescribed Trimbow please visit our Trimbow patient and carer site.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.